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INTRODUCTION
With increasing use of screening computed tomography (CT) 
scans, more frequent detection of indeterminate pulmonary 
nodules creates a growing need for further clinical evaluation, 
including percutaneous transthoracic fine-needle aspiration 
biopsy (FNAB). Percutaneous transthoracic FNAB has a high 
diagnostic yield for malignancy.1 However, the diagnostic yield 
of FNAB for benign lesions is lower (10–50%),2-5 and widely 
variable false-negative rates (3.8–62.5%) have been reported 
using percutaneous transthoracic FNAB without rapid on site 
evaluation of cytopathology.6-8 One of the major limitations of 
FNAB is that malignancies cannot be excluded without a spe-
cific benign diagnosis, even with a negative cytologic result. 
Although the incidence of positive results on repeated biopsies 
is up to 50% in those with suspected malignancy, the uncer-
tainty must be resolved in cases of nonspecific negative results.9 
Patients with these FNAB results should undergo tissue resa-
mpling with biopsy or surgical resection, or close clinical and 
imaging follow up. A few previous studies have investigated the 
false-negative rates of FNAB and factors related to false-nega-
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tive results.6,8 However, those studies mostly included small 
population sizes and only a few parameters that predict false-
negative lesions. 
Therefore, the purpose of our study was to identify clinical, 
radiologic, and procedure-related factors that predict malig-
nancy in pulmonary lesions with nonspecific benign cytology 
results on percutaneous transthoracic FNAB.
MATERIALS AND METHODS
Institutional Review Board approval was obtained, and in-
formed consent was waived for this retrospective and observa-
tional study.
Patients 
We included a retrospective cohort of patients who underwent 
percutaneous transthoracic FNAB at our institution from March 
2005 to December 2012. Among 1726 pulmonary lesions that 
underwent percutaneous transthoracic FNAB, we included 
only lesions that showed initial “nonspecific benign” cytology 
and had adequate follow up (Fig. 1). The initial cytology results 
from FNAB were classified as positive for malignancy, atypical 
cell (significant but nondiagnostic atypia present), specific 
benign, negative for malignancy (nonspecific benign), or in-
adequate specimen (specimens that did not include pulmo-
nary macrophages or bronchial lining cells).10 Specific benign 
results were defined as a benign lesion (e.g., hamartoma and 
granuloma) or inflammatory cells with a positive bacterial, 
fungal, or mycobacterial culture that could explain the radio-
logic findings. Negative for malignancy was defined as the 
presence of benign cellular material (e.g., inflammatory cells), 
but not specific enough to render a diagnosis. Lesions with re-
sults of positive for malignancy (n=931), “presence of atypical 
cells” (n=63), specific benign (n=56), or inadequate specimen 
(n=312) were excluded from analysis. For adequate follow up, 
the biopsied lesion was either 1) followed for at least 2 years by 
CT demonstrating resolution or no growth; 2) showed com-
plete resolution within 2 years of follow-up CT; 3) had a sub-
sequent surgical biopsy or repeated biopsy of the pulmonary 
lesion (percutaneous transthoracic FNAB or core needle bi-
opsy, or transbronchial lung biopsy); or 4) the patient under-
went a biopsy from another body site. We excluded 134 lesions 
with nonspecific benign cytology results that did not receive 
adequate clinical follow up, and eight lesions because of no 
available CT image data. Five patients underwent FNAB twice 
for the same lesion. Finally, 222 lesions in 217 patients (129 
males and 88 females) were included in the analysis.
FNAB technique
The FNAB procedures were performed by one of three experi-
enced chest radiologists who had 5, 7, and 11 years of experi-
ence performing thoracic biopsies respectively. CT guidance 
was performed with a CT fluoroscopy technique using a 16- 
multidetector CT scanner (Somatom Sensation 16; Siemens 
Medical Solutions, Erlangen, Germany) equipped with CARE 
Vision software (Siemens Medical Solutions). The exposure 
parameters were 120 kV, 30 mAs, and slice thickness of 6 mm. 
Ultrasound (US) guidance was performed using a US system 
(HDI5000; ATL Philips, Bothell, VA, USA) equipped with a 3.5- 
to 5.0-MHz convex probe. The biopsy needle was inserted by 
a freehand out-of-plane approach and then advanced into the 
lesion with real-time visualization. Fluoroscopy-guidance was 
performed using a fluoroscope (Medix 130, Hitachi Med. Corp, 
ExcludedPercutaneous transthoracic
lung biopsy from March 2005 
to February 2012 (n=1845)
Core needle biopsy (n=119)
Fig. 1. Flow diagram of this study. FNAB, fine-needle aspiration biopsy.
Benign (n=107): true negative Malignancy (n=115): false negative Final diagnosis
Excluded
Excluded
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Malignant (n=931)
Atypical cell (n=63)
Inadequate specimen (n=312)
No adequate follow-up (n=134)
No available image data (n=8)
Specific benign (n=56)
Negative for malignancy
(nonspecific benign) (n=364)
FNAB cytology (n=1726)
Benign (n=420)
Study population (n=222)
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Tokyo, Japan). All procedures were performed with the patients 
in a prone, supine, or lateral decubitus position, depending on 
the location of the lesion. The puncture area was cleaned with 
antiseptic solution followed by administration of local anes-
thetic by subcutaneous injection of 1% lidocaine (Xylocaine, 
AstraZeneca, Wilmington, DE, USA). In all cases, at least two as-
piration specimens were obtained using 20- to 22-gauge Chiba 
needles to obtain sufficient specimen. The specimen was placed 
in 99% ethyl alcohol for cytologic examination.
Data analysis
Final diagnosis was determined in review of pathologic results 
or follow-up imaging results. True-negative cases were defined 
as those demonstrating CT stability for at least 2 years, com-
plete resolution of the lesion of interest on follow-up imaging, 
or those that underwent a surgical biopsy that demonstrated a 
benign process. False-negative cases were defined as those in 
which the diagnosis of malignancy was established by patholo-
gy from a subsequent surgical biopsy, repeated biopsy, or from 
biopsy results from another site of the body with an increase in 
size of the primary lung lesion on follow-up imaging.
Data regarding clinical variables were collected, including 
smoking status, number of pack years, history of prior malig-
nancy, and serum tumor marker levels [carcinoembryonic an-
tigen (CEA), cytokeratin 19 fragment (CYFRA 21-1), and squa-
mous cell carcinoma antigen (SCC Ag)]. An elevated serum 
tumor marker level was defined as at least one tumor marker 
with a level higher than the reference value (5.0 ng/mL for CEA, 
3.3 ng/mL for CYFRA 21-1, 1.5 ng/mL for SCC Ag).11,12
CT images obtained at the time of biopsy or within less than 
1 week of FNAB were retrospectively reviewed by two radiolo-
gists (with 2 and 11 years of experience in both reading CT 
scans and performing FNAB, respectively) who were blinded 
to the outcomes of the FNAB and who did not perform any of 
the FNAB procedures. Final decisions were made through 
consensus reading when there was a discrepancy between 
observers. The radiologic variables analyzed for each lesion 
included the size of the lesion, location of the lesion (upper, 
middle, or lower), and lesion characteristics [solid, subsolid, 
or consolidation in appearance; presence of necrosis (low-
density area or poorly-enhancing area); cavitation within the 
lesion]. We also collected information on FNAB procedure-
related variables that might affect the results, including the dis-
tance between the pleura, the type of imaging modality used 
for guidance, the number of aspirated samples, and whether 
there were complications at any point during or immediately 
after the procedure (e.g., pneumothorax or hemoptysis). When 
lesions had subsolid characteristics, whether the FNAB needle 
approached the solid portion or ground-glass portion was also 
assessed.
Recent (within 3 months of FNAB) positron emission tomog-
raphy (PET) imaging data were also reviewed, if available, by 
an experienced reviewer (with 5 years of experience in nucle-
ar medicine). All 18F-fluorodeoxyglucose (FDG) PET/CT scans 
were obtained with a dedicated PET/CT scanner [Discovery 
Ste (GE Healthcare, Little Chalfont, Buckinghamshire, UK) or 
Biograph TruePoint 40 (Siemens Healthcare, Erlangen, Ger-
many)]. 18F-FDG PET/CT images were reviewed by one nucle-
ar medicine physician using an Advantage Workstation 4.5 
(GE Healthcare). Maximum standardized uptake value (SUV-
max), mean SUV (SUVmean), metabolic tumor volume (MTV), 
and total lesion glycolysis (TLG) on PET images were mea-
sured using volume viewer software. Each biopsied pulmo-
nary lesion was examined with a spheric-shaped volume of 
interest (VOI) that included the entire lesion in the axial, sagit-
tal, and coronal planes. SUVmax of the VOI was calculated as 
(decay-corrected activity/tissue volume)/(injected dose/body 
weight). MTV was defined as the total tumor volume with an 
SUV of 2.5 or greater, and the MTV and SUVmean of the VOI 
were automatically calculated. TLG was calculated as (SUV-
mean)×(MTV).13
For false-negative lesions, the pathology results of final diag-
nosis, the method used to confirm the final diagnosis, and stag-
ing at the time of FNAB were recorded to determine the impact 
of the delay in diagnosis.
Statistical analysis
False-negatives were compared with true-negatives in terms 
A B C
Fig. 2. CT and PET images of a false-negative case of a 45-year-old female. (A) CT image prior to FNAB shows a 2.4 cm subsolid nodule in the right 
lower lobe (arrow). (B) CT image obtained during FNAB shows the needle targeting the subsolid lesion. FNAB cytology result was negative for malig-
nancy. (C) On PET image performed 16 days before FNAB, no increased FDG uptake is seen with the SUVmax measured to be 1.3. Final diagnosis af-
ter surgical resection was invasive adenocarcinoma. CT, computed tomography; PET, positron emission tomography; FNAB, fine-needle aspiration 
biopsy; FDG, fluorodeoxyglucose; SUVmax, maximum standardized uptake value.
http://dx.doi.org/10.3349/ymj.2016.57.5.12431246
Predictor of False-Negative Results of FNAB
A B C
Fig. 3. CT and PET images of a false-negative case of a 64-year-old female. (A) CT image prior to FNAB shows a 3.7 cm solid mass in the left upper 
lobe. (B) CT image obtained during FNAB shows the needle targeting the solid nodule. FNAB cytology result was negative for malignancy. (C) On PET 
image performed 1 day after FNAB, increased FDG uptake is seen with the SUVmax measured to be 30.5. Final diagnosis after surgical resection was 
invasive adenocarcinoma. CT, computed tomography; PET, positron emission tomography; FNAB, fine-needle aspiration biopsy; FDG, fluorodeoxyglu-
cose; SUVmax, maximum standardized uptake value.
Table 1. Comparison of Clinical, Radiologic, and Procedure-Related Characteristics between False-Negative and True-Negative Lesions
True-negative (n=107) False-negative (n=115) p value
Clinical variables
Age (yrs) 59.6±11.2 62.8±11.3 0.037
Male 63 (58.9) 67 (58.3) 0.966
Smoking 
Current smoker 7 (6.5) 7 (4.6) 0.893
Pack years 15.5±21.3 19.1±26.9 0.231
History of prior malignancy 31 (28.2) 32 (26.5) 0.968
Elevated serum tumor marker 16 (19.5) (n=82) 29 (30.2) (n=96) 0.143
Serum CEA level (n=174) 6.27±16.6 (n=80)  24.6±176 (n=94) 0.319
Serum CYFRA 21-1 level (n=117) 3.22±8.94 (n=49) 5.42±14.8 (n=68) 0.317
Serum SCC Ag level (n=50) 0.836±0.9 (n=22) 1.31±2.7 (n=28) 0.374
Radiologic variables
PET parameters (n=132)
SUVmax 4.4±3.8 (n=46) 7.2±5.5 (n=86) 0.001
MTV2.5 (mL) 10.7±23.6 (n=44) 34.7±68.4 (n=86) 0.004
TLG2.5 44.2±109.6 (n=44) 176.1±371.4 (n=86) 0.003
Size of lesion (mm) 20.9 (14.3–31.2) 25.6 (17.5–44.0) 0.007
Location 0.906
Upper 41 (47.7) 45 (52.3)
Middle 14 (45.2) 17 (54.8)
Lower 52 (49.5) 53 (50.5)
Imaging characteristics 0.007
Solid nodule (n=191) 96 (50.3) 95 (49.7)
Subsolid nodule (n=19) 3 (15.8) 16 (84.2)
Consolidation (n=12) 8 (66.7) 4 (33.3)
Presence of necrosis 32 (59.3) 22 (40.7) 0.087
Presence of cavitation 12 (42.9) 16 (57.1) 0.687
Procedure-related variables
Distance from pleura to lesion (mm) 16.0±14.7 16.6±16.0 0.762
Types of imaging guidance 0.499
CT (n=149) 73 (49.0) 76 (51.0)
Fluoroscopy (n=63) 31 (49.2) 32 (50.8)
US (n=10) 3 (30.0) 7 (70.0)
Number of FNAB samples 1.97±0.17 1.99±0.21 0.445
Complication 19 (17.8) 28 (24.3) 0.3
CEA, carcinoembryonic antigen; CYFRA 21-1, cytokeratin 19 fragment; SCC Ag, squamous cell carcinoma antigen; PET, positron emission tomography; SUVmax, 
maximum standardized uptake value; MTV, mean tumor volume; TLG, total lesion glycolysis; CT, computed tomography; US, ultrasound; FNAB, fine-needle aspira-
tion biopsy.
Data are given as n (%) or mean±standard deviations.
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of clinical, radiologic, and procedure-related variables. For cat-
egorical variables, a chi-square test or Fisher’s exact test was 
performed. For continuous variables, an independent Stu-
dent’s t-test or Mann-Whitney test was performed. For radio-
logic variables of CT images, interobserver variability was as-
sessed using weighted-kappa statistics or intraclass correlation 
coefficients. Univariate and multivariate logistic regression 
analyses were performed to determine significant predictors 
of malignancy. Receiver operating characteristic (ROC) curves 
were calculated to determine the best cutoff values for lesion 
size and PET parameters for differentiating true-negative and 
false-negative lesions. Odds ratio (OR) and 95% confidence 
interval (CI) for differentiating true and false-negative lesions 
were calculated for each variable. Because PET imaging were 
not available for all included lesions, we constructed two mod-
els for multivariate logistic regression analysis (Model 1: PET 
parameter+other variables; Model 2: other variables except 
PET parameter) and compared the area under the ROC curve 
of each logistic regression analysis to identify significant pre-
dictors. A probability value <0.05 was considered significant. 
For statistical analysis we used SPSS software (version 18.0 for 
Microsoft Windows, SPSS Inc., Chicago, IL, USA).
RESULTS
Patient and lesion characteristics
Among 222 lesions, 115 (51.8%) were proven to be false-nega-
tives and 107 (48.2%) were true-negatives at final diagnosis. Of 
the 115 false-negative lesions, final diagnosis was confirmed by 
subsequent surgery in 62 lesions, by repeated biopsy in 33 le-
sions, by biopsy of other sites in nine, and by follow-up CT im-
aging in 11 (mean follow-up period 458.1 days, range 89–1379 
days). Among the 107 true-negative lesions, final diagnosis was 
confirmed by subsequent surgery in 27 lesions, by repeated bi-
opsy in four, by biopsy of other sites in three, and by follow up 
in 73 (mean follow-up period, 1167 days, range 41–2628 days), 
respectively. Compared with true-negatives, false-negative le-
sions had a significantly older age (p=0.037), higher SUVmax, 
TLG, and MTV on PET (p<0.05), larger lesion size (median 25.6 
mm vs. 20.9 mm, p=0.007), and a higher percentage of lesions 
with characteristics of subsolid lesions (p=0.007) (Figs. 2 and 3, 
Table 1). Among 19 subsolid lesions, four had no solid portion, 
and the FNAB needle approached the solid portion of all re-
maining lesions except one.
Interobserver variability for assessment of radiologic 
variables
The intraclass correlation coefficient for agreement between 
the two readers for lesion size was 0.946 (95% CI, 0.930–0.958), 
representing excellent agreement. Weighted kappa values for 
agreement for other radiologic variables were 0.834 (95% CI, 
0.772–0.895) for lesion location, 0.720 (95% CI, 0.583–0.857), 
Table 2. Results of Logistic Regression Analysis for Predictors of False-Negative Lesions on FNAB
Variable Univariate p value
Multivariate 
(Model 1) (n=132)
p value
Multivariate 
(Model 2) (n=222)
p value
Age >60 yrs 1.99 (1.16–3.42) 0.013 1.52 (0.657–3.54) 0.327 1.75 (0.985–3.12) 0.057
SUVmax (>6.7) 4.13 (1.73–9.88) 0.001 4.46 (1.79–11.1) 0.002 N/A N/A
MTV2.5 (>2.25 mL) 2.56 (1.22–5.4) 0.013 N/A N/A N/A N/A
TLG2.5 (>6.6) 2.59 (1.23–5.45) 0.013 N/A N/A N/A N/A
Size of lesion (>13.5 mm) 3.04 (1.46–6.36) 0.003 1.61 (0.549–4.7) 0.387 2.51 (1.16–5.43) 0.02
Lesion characteristics (subsolid nodule) 5.6 (1.58–19.8) 0.008 11.2 (1.36–92) 0.025 5.61 (1.55–20.3) 0.009
Area under the curve of ROC curve N/A N/A 0.738 N/A 0.658
0.069
(Model 1 vs. 
Model 2)
FNAB, fine-needle aspiration biopsy; N/A, non-applicable; SUVmax, maximum standardized uptake value; MTV, mean tumor volume; TLG, total lesion glycolysis; 
ROC, receiver operating characteristic.
Data are presented as odds ratio (95% confidence interval).
Table 3. Clinical Findings of False-Negative Cases (n=115)
Final diagnosis
Adenocarcinoma 52
Squamous cell carcinoma 16
Small cell carcinoma 10
Large cell carcinoma 3
Metastasis 16
Lymphoma 4
Adenosquamous cell carcinoma 1
Non-small cell carcinoma 7
Sarcomatoid 1
Undetermined 5
Method of confirmation of final diagnosis
Surgery 62
Repeated biopsy (FNAB or TBLB) 33
Other site biopsy 9
Follow up 11
Interval to final diagnosis 
Mean 105.1±221.9 days
(range, 0–1379 days)
FNAB, fine-needle aspiration biopsy; TBLB, transbronchial lung biopsy.
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0.988 (95% CI, 0.964–1.0) for presence of necrosis, and 1.0 (95% 
CI, 1.0) for presence of cavitation.
Factors predicting false-negative lesions on FNAB 
cytology
Age >60 years, lesion size >13.5 mm, SUVmax >6.7, MTV >2.25 
mL, and TLG >6.6 were used as best cutoff values for logistic 
regression analysis. Univariate logistic regression analysis 
showed that age, increased FDG uptake on PET (SUVmax, 
MTV, and TLG), lesion size, and subsolid lesion characteristics 
were significant predictors of false-negative lesions. Among 
the PET parameters, we used only SUVmax for multivariate lo-
gistic regression analysis to predict false-negative results, be-
cause the PET parameters showed multicollinearity in multi-
variable analysis and the SUVmax showed the highest OR on 
univariate analysis. On multivariate logistic regression analysis, 
Model 1 showed that SUVmax and lesion characteristics of 
subsolid lesion were significant, independent predictors of 
false-negative results (Table 2). Lesion characteristic and lesion 
size were significant independent predictors in Model 2.
Clinical outcomes of false-negative lesions
The final pathologic results, the method of confirmation of final 
diagnosis, and the interval between FNAB and final diagnosis 
for false-negative lesions are shown in Table 3. Among 90 lesions 
confirmed as primary lung cancer, five cases (5.6%) showed an 
upgrade in staging at the time of final diagnosis, compared with 
the tentative stage at the time of FNAB (Table 4).
DISCUSSION
This study demonstrated that increased FDG uptake on PET, 
large lesion size, and subsolid lesion characteristics are inde-
pendent predictors of false-negative pulmonary lesions after 
obtaining nonspecific benign cytologic results from percutane-
ous transthoracic FNAB. After evaluation of multiple clinical, 
radiologic, and procedure-related factors, SUVmax >6.7, lesion 
size over 13.5 mm, and subsolid lesion characteristics were re-
vealed to be significant predictors of false-negative results in 
different models of multivariate logistic regression analysis. Age 
over 60 years was a significant predictor on univariate analysis, 
but not on multivariate logistic regression analysis.
In clinical practice, early diagnosis of lung malignancy is im-
portant for proper management of the patients. Although trans-
thoracic FNAB has been suggested as a nonsurgical technique 
for obtaining histopathologic diagnosis from suspicious pul-
monary lesions, the major limitation of this procedure is its rel-
atively low diagnostic yield for specific benign lesions with vari-
able false-negative rates in the diagnosis of pulmonary nodules 
or masses. Therefore, patients with suspected lung malignancy 
and nonspecific benign cytologic results on initial FNAB often 
require a second biopsy such as surgical biopsy.Ta
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Several studies have investigated the false-negative rates of 
FNAB and factors related to false-negative results.6,8 These stud-
ies suggested a few factors predictive of false-negative results, 
for example large lesion size and occurrence of pneumothorax. 
In our study, large lesion size was a significant predictor on lo-
gistic regression analysis, but the other factors were not signif-
icant. Large lesion size may increase false-negative rates be-
cause the portion of the lesion with malignant cells is probably 
part of a larger consolidation, making it difficult to distinguish 
the primary lesion from surrounding atelectasis or inflamma-
tion.6 Occurrence of pneumothorax has been reported to limit 
the ability to put the needle tip in the lesion and also the num-
ber of passes, which can lead to a decrease in diagnostic yield 
of percutaneous transthoracic FNAB.6,14 However, the occur-
rence of procedure-related complications including pneumo-
thorax was not significantly different between true-negative 
and false-negative lesions in our study. Our study also dem-
onstrated that higher FDG uptake and subsolid lesion charac-
teristics were all significant predictors for false-negative le-
sions. In addition to the well-known utility of PET for diagnosis, 
staging, and prediction of prognosis in lung cancer,15,16 we sug-
gest that PET can be used for the prediction of false-negative 
lesions on FNAB.
Subsolid lesions are known to have lower diagnostic accura-
cy on FNAB than solid pulmonary nodules due to their low cel-
lularity, particularly in pure ground-glass nodules.17 Additional-
ly, on pathologic examination, the probability of interpretation 
error may be high for adenocarcinomas, which are usually 
pathologic determinants of subsolid lesions present on CT. A 
recent study regarding false-negative results from FNAB speci-
mens reported that most interpretation errors in false-negative 
cases (8 of 11, 72.7%) were confirmed as adenocarcinoma.18 
They suggested that a diagnosis of adenocarcinoma can some-
times be difficult to confirm, particularly when necrosis is 
abundant. In our study, 54 of 115 false-negative cases (47.0%) 
were confirmed as adenocarcinoma (52 primary and two met-
astatic adenocarcinomas) on final analysis.
Numerous studies have documented close correlations be-
tween CT and pathologic findings in patients with lesions in the 
spectrum of adenocarcinomas of the lung. Subsolid nodules on 
CT may represent atypical adenomatous hyperplasia (AAH), 
adenocarcinoma in situ, minimally invasive adenocarcinoma, 
or lepidic predominant invasive adenocarcinoma.19-21 Small 
persistent pure ground-glass nodules, particularly those small-
er than 5 mm, often represent foci of AAH; in contrast, the larg-
er the solid component of a lesion, the worse the prognosis.22-29 
Therefore, solitary subsolid nodules or dominant nodules 
among multiple subsolid nodules (solid component >5 mm) 
should be considered malignant and be recommended for 
transthoracic biopsy or surgical excision.30 Considering the low 
diagnostic yield of transthoracic FNAB for subsolid nodules, 
transthoracic core needle biopsy or surgical excision would be 
better methods for tissue confirmation.
Previous studies have reported a wide range of false-negative 
rates of percutaneous transthoracic FNAB.6-8,10,31,32 The false-
negative rate (51.8%) of our study is within the range of previ-
ous results, but is relatively high. Possible reasons for this high 
false-negative rate, compared with other studies, are different 
inclusion criteria, such as a relatively long follow-up period of 
over 2 years, different definition of negative lesions, the absence 
of an on-site cytologist, and exclusion of lesions with core bi-
opsy. We excluded lesions without cytopathologic confirma-
tion or at least 2 years of imaging follow up, as such lesions may 
have a high probability of being benign. Studies on the diag-
nostic performance of percutaneous transthoracic FNAB vary 
regarding the definition of ‘negative lesions’. Some studies in-
cluded cases with inadequate specimen or specific benign re-
sults in the negative category. This variation in definition may 
result in a wide range of reported false-negative rates. In our 
study, lesions with inadequate specimens were not included 
because such lesions have been reported to show a higher false-
negative rate than lesions with nonspecific benign results, 
mostly because of the higher possibility of sampling error with 
an inadequate specimen.8,10 A number of studies have report-
ed the value of having a cytologist present at the time of a biop-
sy procedure to reduce the number of biopsy specimens re-
quired to achieve a diagnosis.33-35 Although many institutions 
have on-site cytologists, the lack of one in our study might lead 
to an increased risk of sampling errors, thus the aspirated speci-
men might not accurately represent the lesion characteristics. 
However, this is not possible in many centers, including our 
institution. Because an on-site cytologist was not available, we 
included only lesions with nonspecific benign results. Many 
studies reported the diagnostic value of core needle biopsy in 
transthoracic biopsy, in terms of higher diagnostic accuracy 
than FNAB alone, by reducing sampling error due to obtaining 
large amounts of sample.36-39 However, we did not include le-
sions that were biopsied with core needle, because only a small 
number of referred pulmonary lesions (119 of 1829 lesions, 
6.5%) underwent core needle biopsy for varying reasons, such 
as high risk of procedure-related complications or preference of 
biopsy-performing radiologists or referring clinicians.
Our study has several limitations. First, because of the retro-
spective nature of the study, some degree of selection bias was 
present and a relatively high false-negative rate was obtained. 
Many lesions lacking an adequate follow-up period were ex-
cluded and most of these had a high probability of being be-
nign. Nonetheless, the false-negative rate (51.8%) of our study 
was within the range of previous results. Second, as rapid on 
site evaluation of cytopathology was not available in the FNAB 
room, we excluded lesions with inadequate specimen from 
the analysis to reduce the impact of sampling error. Third, PET 
parameters were significant predictors for false-negative re-
sults; however, these quantitative parameters were not avail-
able in all patients. Therefore, we constructed two models of 
multivariate logistic regression analysis. Fourth, because only 
http://dx.doi.org/10.3349/ymj.2016.57.5.12431250
Predictor of False-Negative Results of FNAB
a small number of false-negative lesions (5 cases) showed an 
upgrade in staging at the time of final diagnosis, the impact of 
delayed diagnosis on prognosis in cases with false-negative 
results on FNAB could not be determined. However, all five 
cases were terminal stage (stage 3b or 4 in non-small cell can-
cer and extended stage for small cell lung cancer) at the time 
of final diagnosis. Therefore, delayed diagnosis may be critical 
for patient management and prognosis. 
In conclusion, despite the common use of FNAB, there are 
appreciable numbers of false-negative results after the initial 
FNAB. Among the clinical, radiologic, and procedure-related 
factors analyzed, high FDG uptake, large lesion size, and sub-
solid lesion were useful factors for predicting malignancy in 
pulmonary lesions with nonspecific benign cytology results on 
FNAB. Therefore, lesions with these characteristics should be 
more carefully followed up or considered for re-biopsy.
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